Overview

BioDuro’s Oncology department is committed to providing high quality preclinical services to support anti-cancer drug discovery in 2D and 3D cellular models and animal tumor models. With an experienced scientific team and a panel of validated assays and cancer animal models, we assist pharmaceutical companies and academic researchers in the discovery of novel drug targets and evaluation of anti-cancer compounds or biologicals.

BioDuro Advantage

• Experienced scientific team with a strong background in cancer biology
• Combination of classic and cutting-edge cancer research models and platforms
• Dedicated and collaborative project management
• High quality, time and cost efficient services to clients
• Advanced laboratory equipment and a state of the art AAALAC accredited vivarium
• Integrated drug discovery solutions with Medicinal Chemistry, DMPK, and Formulation Development

Services

• Oncology therapeutic target discovery and validation
• Compound and biologics efficacy and early safety evaluation
• Consultation
• Oncology drug discovery

Capabilities

• Cellular model based assays:
  • Cancer cell 2D culture, 3D spheroid culture, and the hTME-3DX Screen and Verify™  (a sophisticated, more physiologically relevant 3D model recapitulating the patient tumor microenvironment)
  • Drug target discovery and validation: RT-PCR, Western blot, IHC, FACS, ELISA, CRISPR
  • Drug efficacy evaluation: enzymatic and biochemistry assays, cell proliferation assay (MTT, CTG, BrdU, alamarBlue)
  • Cancer cell apoptosis, migration, invasion assays
• Cancer animal models:
  • More than 200 available cancer cell lines and CDX models
  • More than 100 PDX models
  • 11 available syngeneic mouse tumor models (useful for immuno-oncology models)
  • 12 Luciferase labeled cancer cell lines and CDX models
  • Live phase tumor imaging for luciferase-labeled CDX
  • Subcutaneous and orthotopic tumor models
  • Experimental metastatic tumor models
  • Systematic leukemia, lymphoma and multiple myeloma models
  • PK/PD, general early toxicity study
  • Histology and IHC analysis
  • Downstream signal and biomarker analysis (RT-PCR, western blot, FACS)
• Immuno-oncology:
  • PBMC, B, T, NK cell isolation
  • T and NK cells activation and proliferation
  • Immuno-phenotyping with multi-color FACS
  • Immunocytes and cytokine infiltration assay in 3D tumor cell spheroids
  • Multiplex cytokine analysis, MSD
  • PBMC and NK cells mediated cytotoxicity
  • Antibody dependent cell-mediated cytotoxicity assay with multiple assay formats